Segall Bryant & Hamill LLC bought a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 76,267 shares of the healthcare company's stock, valued at approximately $1,274,000. Segall Bryant & Hamill LLC owned approximately 0.11% of InMode at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Fox Run Management L.L.C. acquired a new stake in InMode in the 4th quarter valued at approximately $660,000. KLP Kapitalforvaltning AS acquired a new stake in InMode in the 4th quarter worth $745,000. American Century Companies Inc. bought a new position in shares of InMode during the 4th quarter worth about $299,000. Teacher Retirement System of Texas acquired a new position in shares of InMode during the fourth quarter valued at about $306,000. Finally, Intech Investment Management LLC lifted its stake in shares of InMode by 36.3% in the fourth quarter. Intech Investment Management LLC now owns 42,300 shares of the healthcare company's stock valued at $706,000 after buying an additional 11,260 shares during the period. 68.04% of the stock is owned by institutional investors and hedge funds.
InMode Stock Performance
NASDAQ:INMD traded up $0.04 on Monday, hitting $17.74. 1,870,219 shares of the stock were exchanged, compared to its average volume of 1,164,323. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $21.76. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 7.55 and a beta of 2.08. The company's 50-day moving average price is $18.32 and its 200 day moving average price is $17.78.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of InMode in a report on Tuesday, February 4th. Barclays boosted their price target on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, InMode presently has an average rating of "Hold" and a consensus price target of $22.25.
Read Our Latest Report on InMode
InMode Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
See Also
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
